- Home
- WING vs VKTX Comparison
WING vs VKTX Comparison
Compare WING & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WING | VKTX |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.1B |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | WING | VKTX |
|---|---|---|
| Price | $130.70 | $31.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 27 | 7 |
| Target Price | ★ $295.92 | $95.86 |
| AVG Volume (30 Days) | 1.4M | ★ 2.2M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | ★ 67.84 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $696,853,000.00 | N/A |
| Revenue This Year | $17.20 | N/A |
| Revenue Next Year | $15.86 | N/A |
| P/E Ratio | $123.95 | ★ N/A |
| Revenue Growth | ★ 11.35 | N/A |
| 52 Week Low | $133.80 | $22.96 |
| 52 Week High | $388.14 | $43.15 |
Technical Indicators
Market Signals| Indicator | WING | VKTX |
|---|---|---|
| Relative Strength Index (RSI) | 24.84 | 42.91 |
| Support Level | N/A | $30.41 |
| Resistance Level | $267.86 | $36.09 |
| Average True Range (ATR) | 11.62 | 1.70 |
| MACD | -4.49 | -0.18 |
| Stochastic Oscillator | 1.08 | 35.42 |
Price Performance
Historical ComparisonAbout WING Wingstop Inc.
Wingstop is a fast casual restaurant concept built around a simple chicken-centric menu. The firm primarily offers bone-in and boneless wings, tenders, and a chicken sandwich, customizable across 12 flavors. The banner generated $5.3 billion in system sales in 2025 across 3,056 units, with 85% located in the US. Wingstop largely operates as a franchisor, with 98% of units franchised, and earns revenue largely from collecting royalties and advertising fees paid by franchisees, with a smaller contribution from company-owned restaurant sales.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.